Kura Oncology reports $2.1M KOMZIFTI net revenue in first 5 weeks post-launch; cash at $667M

Kura Oncology, Inc.

2025-FY EPS reported -$3.18 vs consensus -$0.49 ▼ miss (-542.9%)

$2.1M KOMZIFTI net product revenue from Nov 21 to Dec 31, 2025 (first commercial sales).
$195M milestone payment from Kyowa Kirin in Q4 2025; non-cash collaboration revenue $15-17M.
Cash, cash equivalents & short-term investments $667.3M as of Dec 31, 2025.
KOMZIFTI granted full FDA approval in Nov 2025 for R/R NPM1-mutated AML; NCCN Category 2A.
2026 guidance: non-cash collaboration revenue $45-55M; pipeline milestones include Phase 3 trial enrollment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.